Strong Overall Sales Growth
Sales grew 9% as reported and 8% in constant currency. Instruments grew mid-single digits, with high single-digit growth in LC and mass spec portfolio.
Significant Growth in Recurring Revenue
Recurring revenue grew 11%, driven by 9% service growth and double-digit chemistry growth.
Pharma Segment Growth
Pharma grew low double digits, led by strong instrument replacement activity and new product adoption, particularly among large pharma and CDMO customers.
Positive Performance in China
China grew double digits with strength across all end markets, driven by CDMOs and battery testing in the industrial segment.
Raising Full-Year Guidance
Full year 2025 constant currency sales growth guidance raised to 5.5% to 7.5% and non-GAAP EPS guidance to $12.95 to $13.05.